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INTRODUCTION
Eosinophilic fasciitis is a rare disease character-
ized by skin alterations such as scleroderma, pe-
ripheral eosinophilia, hypergammaglobulinemia, 
and high erythrocyte sedimentation rate.1 It more 
frequently involves the inferior limbs. The absence 
of Raynaud’s phenomenon or sclerodactyly distin-
guishes Eosinophilic fasciitis from sclerodermia.1 
Literature has described fewer than 300 cases. 
Shulman syndrome, as it is also known, was first 
described in 1974. Its etiology remains unknown.2 It 
affects both sexes equally, with a higher incidence 
among individuals of 40-50 years old and no associa-
tions of race, risk factors, or family history.3
The importance of this case is related to the rar-
ity of the disease, its atypical presentation, and the 
difficulty of its treatment. The reduced number of 
reported cases makes it harder to approach these 
situations and emphasizes the importance of sharing 
any experience.
We present the case of a 27-year-old woman with 
Eosinophilic fasciitis characterized by symmetrical 
peripheral edema and maculopapular skin rash.
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Eosinophilic fasciitis, or Shulman’s disease, is a rare disease of unknown etiology. It is characterized by peripheral eosinophilia, hyper-
gammaglobulinemia, and high erythrocyte sedimentation rate. The diagnosis is confirmed by a deep biopsy of the skin. The first line 
of treatment is corticotherapy.
We present a rare case of eosinophilic fasciitis in a 27-year-old woman with an atypical presentation with symmetrical peripheral ede-
ma and a Groove sign. The patient responded well to treatment with corticosteroids at high doses and, in this context, was associated 
with hydroxychloroquine and azathioprine. After two and a half years, peripheral eosinophilia had increased, and more of her skin had 
hardened. At that time, the therapy was modified to include corticoids, methotrexate, and penicillamine. It is of great importance to 
publicize these cases that allow us to gather experience and better treat our patients.
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CASE REPORT
We report the case of a 27-year-old caucasian 
woman who works as a secretary. She has diabetes 
mellitus type 1 and hypothyroidism, treated and su-
pervised. She was sent to us because of the emergent 
and progressive deterioration of symmetrical periph-
eral edema (Figure 1), asthenia, and maculopapular 
pruritic rash with a 2-month evolution. She had been 
previously treated with insulin and levothyroxine 
and had no other complaints or relevant history. 
At the objective examination, she presented with 
a hardening of the subcutaneous tissue of the fore-
arms and inferior limbs with symmetric edema, with 
no evidence of arthritis and a maculopapular rash on 
the right arm. Analytically, she presented haemo-
globin of  13.1 g/dL (11.7-15.7), leucocytes  26,3x10^3 
uL (4-10), eosinophils 8.7x10^3 u/L (33%), plaquettes 
650,000 uL (150,000-450,000); sedimentation veloc-
ity of 58 mm/h (<20), LDH 497 U/L (240-480), reac-
tive protein C 18,1 mg/L (<5), antinuclear antibody 
(ANA) 1/320, anti-dsDNA 121,9 UI/mL (<25), rheu-
matoid factor 52 uI/mL (<14) and electrophoresis of 
the serum proteins with a monoclonal peak of IgG 
de 2920 mg/dL (700-1600). The swab of peripheral 
blood showed eosinophilia and lymphocytes (with no 
morphologic alterations), thrombocytes, and some 
giant plaquettes. The myelogram and bone biopsy re-
vealed granulocytic hyperplasia with mature eosino-
phils. We made a nuclear resonance imaging of the 
right hand, which revealed diffuse thickening of the 
subcutaneous cell tissue, associated with edema that 
reached the fascias and the intermuscular planes 
diffusely with no clear predominance; this made it 
reasonable to reconsider the clinical hypothesis of 
fasciitis with confirmation by cutaneous biopsy (Fig-
ure 2). The deep cutaneous biopsy between the sub-
cutaneous cell tissue and the skeletal muscle showed 
the involvement of the fascia by numerous polymor-
phonuclear eosinophils. The remaining examina-
tions, such as capillaroscopy, manometry, breathing 
function proofs, echocardiogram, and computerized 
axial tomography of thorax, abdomen, and pelvis 
did not show any alterations. The examinations led 
us to conclude that it was eosinophilic fasciitis. The 
patient started pulses of methylprednisolone (500 
mg daily for 3 days), followed by 40 mg of oral pred-
nisolone (slowly weaning, during four months, until 
reaching 10 mg/day) as well as hydroxychloroquine 
400 mg/day and azathioprine (AZA) 150 mg/day for 
2.5 years. After that period, she displayed an in-
FIGURE 1: EDEMA OF THE INFERIOR MEMBER
FIGURE 2: RESONANCE IMAGING OF THE RIGHT HAND
crease of peripheral eosinophils with worsening of 
cutaneous complaints (hardening of the skin). She 
repeated pulses of methylprednisolone 1gr monthly 
for 5 months as well as methotrexate 20 mg /week, 
penicillamine 150 mg/day, and hydroxychloroquine 
400 mg/day. One year later, there was an improve-
ment of the subcutaneous hardening maintaining 
hyperpigmentation areas (figure 3).
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DISCUSSION
Fasciitis was first described by Shulman in 1974.4 
Its etiology remains unknown. In literature, the dis-
ease is sometimes said to have been preceded by in-
tense physical activity.1 Some cases are associated to 
other factors, such as the beginning of hemodialysis, 
infection by Borrelia burgdorferi, radiotherapy, he-
matological disturbances, graft versus host disease, 
or medications such as simvastatin, atorvastatin, and 
fenitoin.1,5-8 In our case, no leading factor was detect-
ed. Serologies and cultural examinations were nega-
tive. About 15% of patients have a malign underlying 
disease like leukemia or lymphoma. There are also 
cases described as being associated with hematolog-
ic disturbances, such as aplastic anemia, hemolytic 
anemia, self-immune peripheric thrombocytopenia, 
and pernicious anemia.1 Self-immune diseases like 
Hashimoto Thyroiditis, morphea, systemic sclerosis, 
Sjögren syndrome, and antiphospholipid antibody 
syndrome were also reported in some patients.1 In our 
case, the patient has not presented any malign disease 
so far. She was already under treatment and supervi-
sion for type 1 diabetes mellitus and hypothyroidism.
Patients often present unspecific symptoms like 
weakness, general discomfort, fever, and weight 
loss9. At the objective examination, we noticed a 
hardening of the skin (looking like “peau d’orange”) 
with venous nodes (Groove sign) and occasionally lo-
calized morphea.10 The prayer sign is common, and 
the Raynaud phenomenon is not frequent.10 In this 
case, the patient presented a Groove sign in the right 
forearm and symmetric edema in the inferior limbs, 
which led to the differential diagnosis conditions as-
sociated to low oncotic pressure or venous failure and 
congestive heart failure. It was necessary to consider 
other differential diagnoses with similar symptoms 
and peripheral eosinophilia such as scleroderma, 
systemic sclerosis, eosinophilia-myalgia syndrome, 
and localized fibrosing disorders.5 Analytically, we 
found peripheral eosinophilia, hypergammaglobulin-
emia (generally IgG or IgM) and elevation of the ve-
locity of erythrocyte sedimentation. Our patient pre-
sented peripheral eosinophilia and a peak in IgG with 
no specific antibody.9 The diagnosis is established by 
the histopathological report samples through a deep 
skin biopsy, which must include the muscle. Mag-
netic resonance imaging may prove useful to define 
the area for the biopsy, and later, to monitor the re-
sponse of the disease to the treatment.1 The typical 
findings are thickening of the fascia (twice to fifteen 
times the normal size) associated with inflammato-
ry cells formed by lymphocytes, plasmocytes, his-
tiocytes and eosinophils (in 69-75% of the cases) in 
variable rates. There is no necrotic vascular injury. 
The presence of peripheral eosinophils in the fascia 
is not confirmed in the diagnosis.9 Histologically, the 
differential diagnosis should be done with nodule 
erythema, Wells Syndrome and a reaction to insect 
bites or parasitic diseases.10
Eosinophilic fasciitis is a rare disease, which makes 
the treatment strategy more difficult. Corticotherapy 
is currently the first line of treatment at a dosage of 
1mg/kg/day until analytical normalization and clin-
ic remission. Many patients do not answer to corti-
cotherapy, and in the case of those who do, there may 
be a relapse. In these situations, other immunomodu-
lators are used, such as azathioprine, hydroxychloro-
quine, cyclosporine, dapsone, and methotrexate.7,10,11
The prognosis is generally good, except when an 
underlying malign disease is associated. Diagnosis at 
ages younger than 12 years, the involvement of the 
body, and cutaneous sclerosis such as morphea can 
be evidence of refractory disease.1
CONCLUSION
Eosinophilic fasciitis is a rare disease and its treat-
ment can be a challenge. We have just presented a 
rare case of eosinophilic fasciitis with symmetric pe-
ripheral edema. Patients often present relapsing or 
do not respond to corticotherapy alone. In this case, 
other immunomodulator agents had to be added. It 
is important to spread these experiences, which al-
low us to gather information and knowledge to better 
treat and care for our patients. 
There is no conflits of interesse
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RESUMO
A fasciite eosinofílica ou doença de Shulman é uma doença rara de etiologia desconhecida. É caracterizada por eosinofilia periférica, 
hipergamaglobulinemia e velocidade de sedimentação eritrocitária elevada. O diagnóstico é confirmado por biópsia profunda da pele. 
O tratamento de primeira linha é a corticoterapia.
Apresentamos um caso raro de fasciite eosinofílica numa mulher de 27 anos com uma apresentação atípica com edema periférico 
simétrico e sinal de Groove. A paciente respondeu bem ao tratamento com corticoides, mas em doses elevadas, e, nesse contexto, 
associou-se hidroxicloroquina e azatioprina. Ao fim de dois anos e meio verificou-se aumento de eosinofilia e novamente pele mais 
endurecida. Nessa altura alterou-se a terapêutica para corticoides, metrotexato e penicilamina. É de grande importância a divulgação 
desses casos que nos permitem reunir experiência e assim melhor tratar os nossos doentes.
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